公司董事兼总经理王哲先生、常务副总经理李泓波先生、副总经理吕丰美先 生、董事会秘书颜华先生、财务负责人陈秋芳女士保证向本公司提供的信息内容 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 安徽富乐德科技发展股份有限公司（以下简称"公司"）于2025年11月21 日披露了《关于部分董事、高级管理人员减持股份的预披露公告》，持有安徽富 乐德科技发展股份有限公司（以下简称"公司"）112,000股（占本公司总股本 比例0.0151%） 的王哲先生、持有公司48,000股（占本公司总股本比例0.0065%） 的李泓波先生、持有公司48,000股（占本公司总股本比例0.0065%）的吕丰美先 生、持有公司84,000股（占本公司总股本比例0.0113%）的颜华先生、持有公司 48,000股（占本公司总股本比例0.0065%）的陈秋芳女士，计划在本减持计划公 告之日起十五个交易日后的三个月内，以集中竞价交易方式减持公司股份分别不 超过28,000股、12,000股、12,000股、21,000、12,000股，分别占公司总股本的 0.0038%、 ...

今日具体限售解禁股情况如下： | 股票简称 | 股票代码 | 限售股类型 | 解禁股数 | | --- | --- | --- | --- | | 力生制药 | 002393 | 股权激励限售流通 | 49.7万 | | 雪峰科技 | 603227 | 增发A股法人配售上市 | 9761.72万 | | 苏盐井神 | 603299 | 股权激励限售流通 | 62.27万 | | 千禾味业 | 603027 | 股权激励限售流通 | 204.3万 | | 鸿铭股份 | 301105 | 发行前股份限售流通 | 337.5万 | | 富乐德 | 301297 | 发行前股份限售流通 | 2亿 | | 佰维存储 | 688525 | | 1.14亿 | 智通财经APP获悉，12月30日共有7家上市公司的限售股解禁，解禁总市值约115.51亿元。 ...

上海市锦天城（深圳）律师事务所 法律意见书 法律意见书 上海市锦天城（深圳）律师事务所 关于安徽富乐德科技发展股份有限公司 2025年第四次临时股东会的 上海市锦天城（深圳）律师事务所 地址：深圳市福田中心区福华三路卓越世纪中心 1 号楼 21、22、23 层 电话：0755-82816698 传真：0755-82816898 上海市锦天城（深圳）律师事务所 法律意见书 本法律意见书仅就公司本次股东会的召集、召开程序、召集人和出席会议人 员资格、表决程序、表决资格等发表法律意见，并不意味着本所及律师对本次股 东会议案所述事项的真实性和准确性做出任何明示或默示的评价、意见和保证。 基于上述声明，本所及律师按照律师行业公认的业务标准与道德规范，遵循 诚实、守信、独立、勤勉、尽责的原则，就本次股东会所涉相关事宜发表如下法 律意见： 1 上海市锦天城（深圳）律师事务所 法律意见书 一、本次股东会的召集人资格及召集、召开程序 上海市锦天城（深圳）律师事务所 关于安徽富乐德科技发展股份有限公司 2025年第四次临时股东会的法律意见书 致：安徽富乐德科技发展股份有限公司 上海市锦天城（深圳）律师事务所（以下简称"本所"）接 ...

| 证券代码：301297 | 证券简称：富乐德 | 公告编号：2025-082 | | --- | --- | --- | | 债券代码：124025 | 债券简称：富乐定转 | | 安徽富乐德科技发展股份有限公司 2025年第四次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形； 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开情况和出席情况 1、会议召开时间： 现场会议时间：2025年12月26日下午16:00 网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为2025年12月26日 上午9:15—9:25、9:30－11:30和下午13:00－15:00。 通过深圳证券交易所互联网投票系统投票的具体时间为2025年12月26日上 午9:15至下午15:00。 2、现场会议召开地点：安徽省铜陵市义安经济开发区南海路18号 3、会议召集人：公司董事会 4、会议召开方式：采取现场投票与网络投票相结合的方式 5、会议主持人：董事长贺贤汉 6、股权登记日：2025年1 ...

光大证券股份有限公司 关于安徽富乐德科技发展股份有限公司 部分首次公开发行前已发行股份上市流通的核查意见 光大证券股份有限公司（以下简称"光大证券"或"保荐机构"）作为安徽富 乐德科技发展股份有限公司（以下简称"富乐德"或"公司"）首次公开发行股票 并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券 交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》等相关规定，对公司部分首次公开发行前已发行股份上 市流通事宜进行了核查，具体核查情况如下： 一、首次公开发行股票概况 公司首次公开发行前股份总数253,790,000股，经中国证券监督管理委员会《关 于同意安徽富乐德科技发展股份有限公司首次公开发行股票注册的批复》（证监许 可[2022]2252 号），公司获准首次公开发行人民币普通股（A 股）股票 84,600,000 股，自 2022 年 12 月 30 日起在深圳证券交易所创业板上市。公司首次公开发行完 成后的总股本数为 338,390,000 股。 二、上市后股本变动情况 （1）2025 年 6 月，公司股权激励归属股份产生的股本变动 ...

| 证券代码：301297 | 证券简称：富乐德 | 公告编号：2025-081 | | --- | --- | --- | | 债券代码：124025 | 债券简称：富乐定转 | | 安徽富乐德科技发展股份有限公司 关于首次公开发行前已发行股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次解除限售的股份为安徽富乐德科技发展股份有限公司（以下简称"公 司"）部分首次公开发行前已发行股份； 2、本次解除限售股东户数共计 3 户，解除限售股份的数量为 200,000,000 股，占公司总股本的 26.91%，限售期为自公司首次公开发行并上市之日起 36 个月； 3、本次解除限售的股份上市流通日期为 2025 年 12 月 30 日。 一、公司首次公开发行股份情况和上市后股份变动情况 1、首次公开发行股份情况 经中国证券监督管理委员会《关于同意安徽富乐德科技发展股份有限公司首 次公开发行股票注册的批复》（证监许可[2022]2252 号）同意，公司获准首次 公开发行人民币普通股（A 股）股票 84,600,000 股，并经 ...

Economic Performance - Shanghai's GDP surpassed 4 trillion yuan in the first three quarters, with a financial market transaction volume growth of 12.7% year-on-year [1] - The manufacturing output increased by 8.5% year-on-year, and Shanghai Port's container throughput reached 50.56 million TEUs, expected to set a new annual record [1] - The region's GDP growth for the first three quarters was 5.5%, with strategic emerging industries accounting for 44.1% of the total industrial output [5] Development of "Five Centers" - The "Five Centers" initiative is driving high-quality economic and social development, with a focus on enhancing overall, platform, amplification, and radiation effects [1][4] - The establishment of the IMF Shanghai Center and other international organizations in the region signifies Shanghai's growing importance as a global financial hub [4] - Shanghai has seen a rise in high-tech enterprises, with 25,000 companies and an average of 320 new tech firms emerging daily [5] Innovation and Technology - Innovation is becoming a strategic cornerstone for the "Five Centers" construction, with significant growth in China's biopharmaceutical R&D market [9] - The internal rate of return for China's biopharmaceutical R&D is 8.5%, significantly higher than the 3.6% in the U.S., showcasing China's efficiency in innovation [9] - The city is focusing on key sectors like integrated circuits, biomedicine, and artificial intelligence to enhance its industrial competitiveness [10] Mergers and Acquisitions - Mergers and acquisitions are seen as a vital driver for resource optimization and economic transformation, with Shanghai's "M&A Twelve Articles" promoting a favorable environment for such activities [9][11] - By the end of September, Shanghai completed 25 M&A transactions totaling 220.4 billion yuan, enhancing the core competitiveness of industrial clusters [10] - The "M&A Alliance" aims to support over 1.2 trillion yuan in national M&A transactions and 400 billion yuan in the Shanghai region over the next three years [11] Future Goals and Challenges - The "Fifteen Five" period is viewed as a critical phase for Shanghai's "Five Centers" construction, emphasizing the need for continuous improvement and international benchmarking [12] - Shanghai aims to enhance its international shipping services and financial systems to compete with global leaders like Singapore and London [13] - The city is addressing challenges in offshore finance and cross-border services to strengthen its financial ecosystem [13]

证券日报网讯 12月12日，富乐德（301297）在互动平台回答投资者提问时表示，截至2025年12月10日 收盘，公司股东人数为33385户。 ...

Group 1 - Jinggong Technology signed a sales contract with Hubei Yuchuang worth 729 million yuan, accounting for 42.16% of the company's audited revenue for 2024 [1] - Heshun Electric is expected to win a bid for a State Grid procurement project worth 107 million yuan, representing 24.97% of the company's 2024 revenue [2] - Yongmaotai plans to invest approximately 400 million yuan in a new intelligent manufacturing project for magnesium-aluminum alloy materials [3] Group 2 - Longi Green Energy announced the termination of its plan to issue global depositary receipts abroad, stating it will not significantly impact its operations [4] - Bai Ao Intelligent is expected to win bids for projects totaling 27.5 million yuan [5] - Lian Biological is planning a change of control and asset purchase, leading to a temporary suspension of its stock [6] Group 3 - Bo Rui Communication intends to acquire 51% of Meijing Technology for 66.49 million yuan [7] - Huitai Medical plans to repurchase shares worth 200 to 250 million yuan for employee stock ownership plans [8] - Yifang Biological is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [9] Group 4 - Jiuqiang Biological's shareholders signed an agreement for the transfer of 5% of the company's shares to China National Pharmaceutical Investment [11] - Songcheng Performing Arts plans to repurchase shares worth 100 to 200 million yuan for capital reduction [12] - Zhonghong Medical's subsidiary is expected to be selected for a centralized procurement project in Jiangxi Province [13] Group 5 - Xingfu Electronics plans to invest 480 million yuan in a new electronic-grade phosphoric acid project [14] - Jiaao Environmental Protection's stock will be subject to risk warnings due to an administrative penalty [15] - ST Nuotai received a drug registration certificate for a new injection [16] Group 6 - Haimo Technology plans to sell its controlling subsidiary, Xian Sitian Instrument, for 370 million yuan [17] - Jingce Electronics signed multiple sales contracts with a single customer totaling 433 million yuan [18] - Donghua Testing's controlling shareholder plans to reduce its stake by up to 1.99% [19][20] Group 7 - Xingqi Eye Medicine completed the first subject enrollment for a Phase II clinical trial of its eye drop product [21] - Kute Intelligent's controlling shareholder plans to reduce its stake by up to 2% [22] - Dongcheng Pharmaceutical's subsidiary received approval for a new specification of a heparin sodium injection [23] Group 8 - Zhaoyi Innovation is in the process of issuing H-shares and has received regulatory approval [24] - Aokang International's shareholder plans to reduce its stake by up to 3% [25] - Jiamei Packaging's controlling shareholder is planning a change of control, leading to a temporary stock suspension [26] Group 9 - ST Kevin's stock will have its risk warning lifted and will resume trading [27] - Zaiseng Technology's controlling shareholder plans to transfer 6.04% of the company's shares [28] - Lide New Energy's shareholder plans to reduce its stake by up to 1% [29] Group 10 - Srypu terminated its plan to acquire shares and will resume trading [30] - Longjiang Transportation's subsidiary plans to invest 2.679 billion yuan in a graphite mining project [31] - Haowei Group's controlling shareholder has not reduced its stake and has terminated the reduction plan [32] Group 11 - Huilun Crystal received an administrative penalty notice for information disclosure violations [33] - Haiguang Information terminated a major asset restructuring plan [34] - Zhongke Shuguang announced a cash dividend plan [35] Group 12 - Fushuo Technology's share purchase plan was approved by the Shenzhen Stock Exchange [36] - Dongbai Group's shareholder reduced its stake by 25.95 million shares [38]

格隆汇12月9日丨富乐德(301297.SZ)公布，根据实际经营发展需要，江苏富乐华半导体科技股份有限公 司（简称"富乐华"）拟转让参股公司无锡海古德新技术有限公司（简称"海古德"或"标的公司"）410.07 万股，转让价格合计69,998,949元。本次转让前富乐华持有海古德1,298.561万股，占其总股本比例为 12.87%，转让后富乐华持有海古德888.491万股，占其总股本比例为8.80%。 ...